Literature DB >> 31166758

Concepts in U.S. Food and Drug Administration Regulation of Artificial Intelligence for Medical Imaging.

Ajay Kohli1, Vidur Mahajan2, Kevin Seals3, Ajit Kohli4, Saurabh Jha5.   

Abstract

OBJECTIVE. Although extensive attention has been focused on the enormous potential of artificial intelligence (AI) technology, a major question remains: how should this fundamentally new technology be regulated? The purpose of this article is to provide an overview of the pathways developed by the U.S. Food and Drug Administration to regulate the incorporation of AI in medical imaging. CONCLUSION. AI is the new wave of innovation in health care. The technology holds promising applications to revolutionize all aspects of medicine.

Keywords:  Food and Drug Administration; artificial intelligence

Year:  2019        PMID: 31166758     DOI: 10.2214/AJR.18.20410

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

Review 1.  Ethics of Artificial Intelligence in Medicine and Ophthalmology.

Authors:  Yasser Ibraheem Abdullah; Joel S Schuman; Ridwan Shabsigh; Arthur Caplan; Lama A Al-Aswad
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2021 May-Jun 01

2.  Real-World and Regulatory Perspectives of Artificial Intelligence in Cardiovascular Imaging.

Authors:  Ernst Wellnhofer
Journal:  Front Cardiovasc Med       Date:  2022-07-22

3.  Systematic analysis of the test design and performance of AI/ML-based medical devices approved for triage/detection/diagnosis in the USA and Japan.

Authors:  Mitsuru Yuba; Kiyotaka Iwasaki
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.